Financials
Financial year 2025
LAMBO Laboratoria - LAMBO Laboratoires from Wijnegem, company number BE0404094872, closed financial year 2025 with a result of € 2.7 million after tax. For that financial year LAMBO Laboratoria - LAMBO Laboratoires recorded revenue of € 24.7 million and equity of € 5.3 million. Compared with financial year 2024, the result moved from € 555,199 to € 2.7 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.
€ 5.3 million
▲ 89% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2.7 million
▲ € 2.1 million vs 2024
Profit after tax over the fiscal year.
€ 2.8 million
▲ 164% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 4.9 million.
People and assets in 2025
83.8
▼ 3.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 5.6 million
▲ 3% vs 2024
€ 66,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 19,362
▼ 14% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.8 million
▼ 11% vs 2024
€ 495,188 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 2.4 million
▲ 20% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 57 days on average.
€ 905,622
▲ 34% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 17,475,624 | € 20,522,980 | € 20,563,594 | € 24,675,968 | ▲ 20% |
| Profit after taxes | € -283,773 | € 400,904 | € 555,199 | € 2,700,201 | ▲ € 2.1 million |
| Equity | € 2,159,491 | € 2,259,892 | € 2,808,828 | € 5,296,051 | ▲ 89% |
| Total debts | € 7,341,129 | € 7,829,038 | € 6,095,790 | € 6,763,512 | ▲ 11% |
| Cash | € 340,275 | € 626,027 | € 1,057,976 | € 2,794,787 | ▲ 164% |
| Land & buildings | € 3,410,133 | € 3,123,051 | € 2,965,837 | € 2,806,945 | ▼ 5% |
| Retained profit | € 1,727,415 | € 1,834,079 | € 2,389,278 | € 4,882,763 | ▲ 104% |
| Dividend | € 32,928 | € 294,240 | € 0 | € 0 | |
| Bank debt | € 3,783,362 | € 3,541,513 | € 3,163,738 | € 2,810,590 | ▼ 11% |
| Balance sheet total | € 9,677,386 | € 10,268,047 | € 9,074,131 | € 12,059,562 | ▲ 33% |
| Employees (FTE) | 79.4 | 79 | 87 | 83.8 | ▼ 3.2 |
Key figures of LAMBO Laboratoria - LAMBO Laboratoires, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to LAMBO Laboratoria - LAMBO Laboratoires?
What happened at LAMBO Laboratoria - LAMBO Laboratoires in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- MLC BV stepped down as director. NBB
- Malte Sturm-Wagle stepped down as director. NBB
- ULC BV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 2.7 million (▲ € 2.1 million vs 2024). Source: NBB ↗
- MLC BV became a director. NBB
- Malte Sturm-Wagle became a director. NBB
- ULC BV became a director. NBB
- New establishment in Wijnegem. KBO
In short
From € 283,773 loss in 2022 to € 2.7 million profit in 2025.
Paid € 1.3 million in corporate taxes since 2022.
Best year ever: 2025, with € 2.7 million profit.
Paid out € 327,168 in dividends to the owners in total.
A new publication or filing at LAMBO Laboratoria - LAMBO Laboratoires? We notify you, reason included.
Follow LAMBO Laboratoria - LAMBO LaboratoiresDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by Alphacaps Holding (100%). It owns 12.5% of SPLP itself.
Directors
According to the 2025 annual accounts
Managing director · represented by Michael Leonard
Also active at: Laboratorium Cosdam - Laboratoire Cosdam
since 2025 · until 2032
since 2025 · until 2032
Managing director · represented by Ulric Leonard
Also active at: Laboratorium Cosdam - Laboratoire Cosdam
since 2025 · until 2032
Shareholders
Alphacaps Holding
100%
Participations
SPLP
12.5%
Establishments
Establishment units
Physical locations of this company
Simon De Heuvellaan 4
2110 Wijnegem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0404.094.872
- VAT number
- BE 0404.094.872
- Registered office
- Simon De Heuvellaan 4, 2110 Wijnegem
- Names & denominations
- LAMBO Laboratoria - LAMBO Laboratoires
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 25 September 1952
- Peppol
- Active · Active since 20 Jun 2025
- Activities · NACE
Vervaardiging van andere chemische producten, neg
Vervaardiging van overige farmaceutische producten
Vervaardiging van overige farmaceutische preparaten